Home › Healthcare › Microba Life Sciences (ASX:MAP)

Funding shortfall leaves Microba merger and Takeovers Panel process unresolved

Healthcare By Ada Torres 3 min read

Genetic Signatures has abandoned its proposed merger with Microba Life Sciences after Microba said it lacked the financial capacity to complete the transaction without fresh capital. GSS also declined to provide unsecured working capital funding, leaving the shareholder vote and Takeovers Panel process to be unwound separately.

  • Proposed GSS-Microba merger will not proceed
  • Microba said additional capital was needed to complete the deal
  • GSS declined to provide unsecured working capital funding
  • Resolution 4 will be withdrawn from GSS’s 30 November AGM
  • Further update promised on the Takeovers Panel application

Funding Shortfall Ends Proposed Merger

Genetic Signatures Limited (ASX:GSS) has ended its proposed merger with Microba Life Sciences Limited (ASX:MAP), after Microba disclosed that it did not have enough financial capacity to complete the transaction without raising additional capital. The decision closes a deal that had been under discussion for several months and removes the merger from GSS’s immediate corporate agenda.

The announcement follows Microba trading suspension, which was requested after revised merger terms left the company unable to complete the second tranche of an institutional placement. Microba said it was assessing alternative funding while its cashflow runway narrowed.

GSS Rejects Unsecured Working Capital Funding

GSS said it had discussed providing Microba with unsecured debt funding to support its working capital during implementation of the proposed merger. The GSS board ultimately decided not to proceed, citing the associated risks and potential regulatory requirements.

That decision leaves no disclosed funding bridge for the transaction. GSS has not quantified the financial impact of ending the merger, disclosed any termination or break-fee arrangements, or provided details of any alternative transaction.

Resolution 4 Set for Withdrawal

GSS said it would separately withdraw Resolution 4 from the agenda of its annual general meeting on 30 November. The resolution was linked to the proposed merger, meaning shareholders are no longer being asked to consider that transaction at the scheduled meeting.

The collapse also intersects with the Takeovers Panel challenge brought by BCAL Diagnostics on 13 November. GSS said it would make a further announcement about how the merger’s withdrawal and the removal of Resolution 4 affect that application; the current announcement does not state whether the Panel will proceed.

Microba Funding Position Remains Unresolved

For Microba, the immediate question is how it will fund its operations and any future plans after the proposed merger failed to secure a path to completion. The filing provides no new financing terms or timetable, while GSS’s next disclosures are expected to address the AGM resolution and the Takeovers Panel process rather than outline a replacement deal.

Bottom Line?

The merger is off, but the more immediate test is whether Microba can secure capital while the related regulatory process is resolved.

Questions in the middle?

  • What funding option, if any, will Microba pursue after the merger’s collapse?
  • Will the Takeovers Panel continue considering BCAL Diagnostics’ application?
  • Will GSS disclose any termination costs or financial impact from ending the transaction?

Sources